Axicabtagene Ciloleucel in Patients Ineligible for ZUMA-1 because of CNS Involvement and/or HIV: A Multicenter Experience

Yuen, C. A., Hsu, J.-M., Van Besien, K., Reshef, R., Iwamoto, F. M., Haggiagi, A., Liechty, B., Zhang, C., Wesley, S. F., & Magge, R. (2022). Axicabtagene Ciloleucel in Patients Ineligible for ZUMA-1 Because of CNS Involvement and/or HIV: A Multicenter Experience. Journal of Immunotherapy, 45(5), 254–262. https://doi.org/10.1097/cji.0000000000000416
Authors:
Carlen A. Yuen
Jing-Mei Hsu
Koen Van Besien
Ran Reshef
Fabio M. Iwamoto
Aya Haggiagi
Benjamin Liechty
Cenai Zhang
Sarah F. Wesley
Rajiv Magge
Affiliated Authors:
Carlen A. Yuen
Ran Reshef
Fabio M. Iwamoto
Aya Haggiagi
Rajiv Magge
Columbia Affiliation:
Subjects:
HIV Infections (MeSH)
Lymphoma, Large B-Cell, Diffuse (MeSH)
Neoplasms, Second Primary (MeSH)
Author Keywords:
axicabtagene ciloleucel
yescarta
chimeric antigen receptor therapy
secondary central nervous system lymphoma
human immunodeficiency virus
neurotoxicity
elink
Publication Type:
Article
Unique ID:
10.1097/CJI.0000000000000416
PMID:
35404315
DOI:
10.1097/CJI.0000000000000416
Journal:
Journal of Immunotherapy
Publication Date:
Data Source:
Scopus
Source Link:
View Scopus Record
View Web of Science Record
View PubMed Record

Record Created: